Physician profile
Leiah E Moore
NPI 1164886107
$10,568.04
in general payments reported to CMS, 2019-2025
33 companies · $1,766 in 2025
The $1,766 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $43.03 · 2021: $523 · 2022: $4,230 · 2023: $1,624 · 2024: $2,381 · 2025: $1,766.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,687 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,686.53 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,981.62 | 2019-2023 | |
| Novo Nordisk INC | $1,460.69 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,164.55 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $819.16 | 2023-2025 | |
| Astellas Pharma US INC | $642.14 | 2022-2025 | Veozah, Myrbetriq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $597.37 | 2021-2025 | Xifaxan |
| Glaxosmithkline, LLC. | $473.85 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbott Laboratories | $304.49 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Astrazeneca Pharmaceuticals Lp | $303.93 | 2022-2025 | Airsupra, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $283.74 | 2021-2025 | Jardiance, Ofev |
| Exact Sciences Corporation | $244.79 | 2023-2025 | Cologuard Collection Kit |
| Amgen INC. | $193.72 | 2021-2023 | Repatha, Otezla |
| Merck Sharp & Dohme LLC | $168.00 | 2021-2023 | Belsomra, Steglatro |
| Abbvie INC. | $158.88 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $116.55 | 2021-2023 | Xarelto |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $107.60 | 2023-2025 | Rexulti |
| Biohaven Pharmaceutical Holding Company Ltd. | $67.71 | 2022 | |
| Inspire Medical Systems, INC. | $55.66 | 2024 | Inspire |
| Eisai INC. | $50.87 | 2021-2022 | |
| Dynavax Technologies Corporation | $45.42 | 2022-2025 | Heplisav-B |
| Sanofi-Aventis U.S. LLC | $45.12 | 2025 | |
| Biohaven Pharmaceuticals, INC. | $41.38 | 2021 | |
| Cequr Corporation | $39.12 | 2025 | Cequr Simplicity |
| Bayer Healthcare Pharmaceuticals INC. | $37.26 | 2025 | |
| Biogen, INC. | $26.80 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $25.73 | 2023-2025 | Gemtesa |
| Phathom Pharmaceuticals, INC. | $25.54 | 2024-2025 | Voquezna |
| Alexion Pharmaceuticals, INC. | $16.24 | 2025 | Strensiq |
| Amarin Pharma, INC. | $14.56 | 2022 | |
| Ibsa Pharma INC. | $14.23 | 2025 | Licart, Flector, Tirosint |
| Radius Health, INC. | $14.14 | 2024 | Tymlos |
| Vistapharm, INC. | $13.62 | 2021 | |
| Daiichi Sankyo INC. | $13.56 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leiah Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.